Adverum Biotechnologies to Present at Upcoming Investor Conferences
Jefferies 2016London Healthcare Conference onWednesday, November 16, 2016 at2:40 pm GMT inLondon
- 28th Annual
Piper Jaffray Healthcare Conference onWednesday, November 30, 2016 at4:00 pm ET inNew York
The audio portions of the corporate presentation at
About
Adverum is a gene therapy company committed to discovering and developing novel medicines that can offer life-changing benefits to patients living with rare diseases or diseases of the eye who currently have limited or burdensome treatment options. Adverum has a robust pipeline that includes product candidates to treat wet AMD, A1AT deficiency, and hereditary angioedema. Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with
Contact for Adverum:Jill Steier Senior Vice PresidentThe Trout Group LLC 646-378-2946 jsteier@troutgroup.com